RPS6KA1 is a histone acetylation-related oncoprotein in acute myeloid leukemia which is targeted by afzelin
Histone acetylation status is closely associated with AML patient prognosis. RPS6KA1 acts as an oncoprotein in AML, facilitating disease progression. Afzelin may represent a novel therapeutic agent for AML by targeting RPS6KA1, which requires validation by clinical trials.
Authors
- Yongbin Ye
- Xiaomin Niu (ORCID: https://orcid.org/0000-0003-1079-1785)
- Xiaojuan Guo
- Huiqing He
- Guinian Huang (ORCID: https://orcid.org/0000-0001-8493-2259)
- Dafa Qiu
- Ziwen Guo (ORCID: https://orcid.org/0000-0002-8814-6340)
Institutions
- Zhongshan People's Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12885-024-12886-3
- Citations
- 4
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.94